Search clinical trials for: Complement C1 Inhibitor Protein

Total 11020 results

Alimentiv Inc.
Alimentiv Translational Research Consortium

Terminated

Identification of Biomarkers of Janus Kinase Inhibitor Therapy in Patients With Ulcerative Colitis (PROPHETIC)

Ulcerative Colitis

Netherlands
Leiden University Medical Center
Galapagos NV

Recruiting

JAK Inhibition in Ulcerative Colitis

Colitis, Ulcerative

Netherlands
Institute of Cancer Research, United Kingdom

Active, not recruiting

Stereotactic Body Radiotherapy for the Treatment of OPD (HALT)

NSCLC

United Kingdom, France, Switzerland, Italy, Spain
Universitätsklinikum Hamburg-Eppendorf
German Federal Ministry of Education and Research; University Hospital Heidelberg

Recruiting

Stop of Proton-pump Inhibitor Treatment in Patients With Liver Cirrhosis - a Double-blind, Placebo-controlled Trial (STOPPIT)

Liver Cirrhosis

Germany
IDEAYA Biosciences

Recruiting

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Colorectal Cancer | Metastatic Uveal Melanoma | Cutaneous Melanoma | Other Solid Tumors

United States, Australia, Canada
Ain Shams University

Completed

Human Epididymis Protein 4 in Endometrial Carcinoma

Endometrial Cancer

Egypt
University of Rochester

Terminated

Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery

Esophageal Cancer

United States
Barbara Ann Karmanos Cancer Institute
AstraZeneca

Withdrawn

Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer
National Taiwan University Hospital

Unknown

The Impact of Antibiotics MIC Value on the Efficacy of Treatment Regimens for Helicobacter Pylori Infection.

Helicobacter Pylori Infection

Taiwan
Queen Mary University of London

Completed

The Effect of Food Supplements on Food Intake and Gut Hormone Levels

Obesity | Endocrine; Obesity | Appetite; Perverted

United Kingdom
Albany Research Institute, Inc.

Completed

Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in Rosacea (TOMIR)

Rosacea, Erythematotelangiectatic

United States
Karolinska Institutet
University of Copenhagen; Norwegian University of Science and Technology; University... and other collaborators

Completed

Nordic Gastric and Esophageal Tumor Study (NordGETS)

Cancer of the Esophagus | Drug Use | Cancer of Stomach

Sweden
Tesaro, Inc.

Completed

A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas

Solid Tumors | Lymphomas

United Kingdom, United States, Taiwan, Spain, Poland
Kami Maddocks, MD

Active, not recruiting

PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia

Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Refractory/Relapsed Chronic Lymphocytic Leukemia

United States
Qianfoshan Hospital

Completed

Risk Factors and Machine Learning Model for Proton Pump Inhibitor Related Acute Kidney Injury

Acute Kidney Injury | Proton Pump Inhibitor

China
Gangnam Severance Hospital

Completed

Pain After Endoscopic Submucosal Dissection

Gastric Neoplasm

Korea, Republic of
Shanghai East Hospital

Active, not recruiting

A Study to Evaluate JAK Inhibitor Cream in EGFR-inhibitor-induced Skin Rash

Acneiform Eruptions

China
Pfizer

Completed

A Pilot Study To Investigate The Effect Of Concurrent Antacid Administration On The Bioavailability Of Six Experimental Formulations Of Palbociclib

Healthy

United States
Beijing 302 Hospital

Recruiting

Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCC

Liver Neoplasms

China
Pfizer

Terminated

Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis

Plaque Psoriasis

United States, Canada
Uma Borate

Recruiting

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia With FLT3/ITD Mutation | Acute Myeloid Leukemia With KMT2A Rearrangement | Acute Myeloid Leukemia With NPM1 Mutation

United States
Pfizer

Completed

A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer

Non Small Cell Lung Cancer

United States, Australia
Incyte Corporation

Terminated

Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)

COVID-19

United States, Russian Federation
Seoul National University Bundang Hospital

Terminated

The Efficacy of the 7 Days Tailored Therapy as 2nd Rescue Therapy for Eradication of H. Pylori Infection

Helicobacter Infection

Korea, Republic of
Indonesia University
Singapore General Hospital

Not yet recruiting

Medical Thoracoscopy for Undiagnosed Transudative and Exudative Pleural Effusions

Pleural Effusion

Indonesia
National Science Council, Taiwan

Unknown

Prevention of Esophageal Variceal Rebleeding

Esophageal Variceal Rebleeding
Hoffmann-La Roche

Completed

Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. (STARTRK-1)

Locally Advanced Solid Tumors | Metastatic Solid Tumors

United States, Korea, Republic of
Peking University Cancer Hospital & Institute

Not yet recruiting

Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma

Collecting Duct Carcinoma

China
Chroma Therapeutics

Completed

Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours

Solid Tumor

Netherlands, United Kingdom
University of Bern
University of Zurich; Swiss National Science Foundation; Centre Hospitalier Universitaire... and other collaborators

Not yet recruiting

Deprescribing Inappropriate Proton Pump Inhibitors (DROPIT)

Reflux Disease | Inappropriate Prescribing | Proton Pump Inhibitors

Switzerland
University Medical Center Goettingen
Ludwig-Maximilians - University of Munich; University of Leipzig; University... and other collaborators

Recruiting

PROTon Pump Inhibitors and Stent OCclusion Rate Of Lumen Apposing Metal Stents (PROTOCOL)

Acute Pancreatitis

Germany, Austria
Massachusetts Eye and Ear Infirmary

Withdrawn

Longitudinal Study of Children With a Chronic Cough and the Impact of Gastroesophageal Reflux

Cough | Gastroesophageal Reflux
Tang-Du Hospital

Not yet recruiting

Baricitinib for the Lung Injury Following Spontaneous SAH (BLISS)

Spontaneous Subarachnoid Hemorrhage
LaNova Medicines Zhejiang Co., Ltd.

Not yet recruiting

LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.

Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
Changi General Hospital

Completed

Hypomagnesemia Associated With Proton-Pump Inhibitor Use (PPI_HypoMg)

Arrhythmias, Cardiac | Seizures | Hypocalcemia | Hypokalemia | Hypomagnesemia | Proton Pump Inhibitor Adverse Reaction

Singapore
Vanderson Geraldo Rocha

Terminated

Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19 (RUXO-COVID)

SARS-CoV2 | Severe Acute Respiratory Syndrome Coronavirus 2

Brazil
Shanghai Ninth People's Hospital Affiliated to...

Recruiting

Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma (IMplus)

Head and Neck Squamous Cell Carcinoma

China
Sameek Roychowdhury

Active, not recruiting

Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.

Malignant Neoplasm

United States
The First Affiliated Hospital of Xiamen University

Recruiting

Characterizing Myositis With 68Ga-FAPI PET/CT

Myositis | Idiopathic Inflammatory Myopathies

China
Shenzhen People's Hospital
Innovent Biopharmaceutical Co., Ltd.

Active, not recruiting

Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia

Efficacy and Safety | Heterozygous Familial Hypercholesterolemia | PCSK9

China
New Mexico Cancer Care Alliance
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas

Sarcoma

United States
Zhongnan Hospital

Recruiting

Fibroblast Activation Protein Inhibitor PET/CT Imaging in Malignant Tumor of Digestive System

Gastrointestinal Cancer

China
Ruijin Hospital

Recruiting

BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced Sarcoma (BIOVAS)

Sarcoma

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Unknown

Tolerability, Safety, Pharmacokinetics and Efficacy of HS-10241 Single Agent or Combined With Apatinib in Patients With Advanced Solid Tumors (HS:Hansoh;)

Advanced Cancer

China
Chong Kun Dang Pharmaceutical

Completed

Safety and Pharmacokinetic Profile of CKD-581 (CKD-581)

Lymphoma | Multiple Myeloma

Korea, Republic of
Ruijin Hospital

Active, not recruiting

Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy (PROACH)

Pulmonary Metastases | Osteosarcoma | Apatinib

China
First Affiliated Hospital Xi'an Jiaotong University

Recruiting

The Efficacy and Safety of JAK Inhibitor in the Treatment of Anti-MDA5 Antibody-positive Dermatomyositis Patients

Dermatomyositis, Adult Type

China
UNC Lineberger Comprehensive Cancer Center
GlaxoSmithKline

Completed

LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations

Unresectable Melanoma | Stage IV Melanoma | Stage III Melanoma | BRAF Mutant Melanoma

United States
Hannover Medical School

Completed

Efficacy Study of Temsirolimus to Treat Head and Neck Cancer (TEMHEAD)

Head and Neck Squamous Cell Carcinoma

Germany
Sun Yat-sen University

Recruiting

bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC

Liver Diseases | Hepatocellular Carcinoma | Immunotherapy | Camrelizumab | Lenvatinib

China

Search clinical trials for: Complement C1 Inhibitor Protein

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations